Background The clinical significance of combined malonic and methylmalonic aciduria due to ACSF3 deficiency (CMAMMA) is controversial. In most publications, affected patients were identified during the investigation of various complaints. Methods Using a cross-sectional multicenter retrospective natural history study, we describe the course of all known CMAMMA individuals in the province of Quebec. Results We identified 25 CMAMMA patients (6 months to 30 years old) with a favorable outcome regardless of treatment. All but one came to clinical attention through the Provincial Neonatal Urine Screening Program (screening on day 21 of life). Median methylmalonic acid (MMA) levels ranged from 107 to 857 mmol/mol creatinine in urine (<10) and from 8 to 42 μmol/L in plasma (<0.4); median urine malonic acid (MA) levels ranged from 9 to 280 mmol/ mol creatinine (<5). MMA was consistently higher than MA. These findings are comparable to those previously reported in CMAMMA. Causal ACSF3 mutations were identified in all patients for whom genotyping was performed (76% of cases). The most common ACSF3 mutations in our cohort were c.1075G > A (p.E359K) and c.1672C > T (p.R558W), representing 38.2 and 20.6% of alleles in genotyped families, respectively; we also report several novel mutations. Conclusion Because our province still performs urine newborn screening, our patient cohort is the only one free of selection bias. Therefore, the favorable clinical course observed suggests that CMAMMA is probably a benign condiAlina Levtova and Paula J. Waters contributed equally to this work. 
Introduction
Combined malonic and methylmalonic aciduria due to ACSF3 deficiency, termed non-classical combined malonic and methylmalonic aciduria, or CMAMMA, has been reported in 21 patients to date. Its clinical significance remains controversial.
ACSF3 encodes a mitochondrial acyl-CoA synthetase with high specificity for malonate and methylmalonate (Witkowski et al 2011) , essential for the intramitochondrial synthesis of malonyl-CoA, the starting point for mitochondrial de novo fatty acid synthesis. CMAMMA caused by ACSF3 deficiency is therefore entirely distinct from "classical" methylmalonic acidurias due to deficiency of methylmalonyl-CoA mutase or to deficient synthesis of its cofactor adenosylcobalamin.
CMAMMA is also distinguishable from the other condition with increases of both malonic and methylmalonic acids: malonic aciduria due to deficiency of malonyl-CoA decarboxylase. The latter is a severe condition with frequent episodes of metabolic acidosis and hypoglycaemia, cardiomyopathy, neurodevelopmental abnormalities, seizures, renal dysplasia, and markedly high excretion of malonic acid (MA) (Brown et al 1984; MacPhee et al 1993; Gregg et al 1998; Celato et al 2013) with mildly elevated excretion of methylmalonic acid (MMA) (Brown et al 1984; MacPhee et al 1993; Gregg et al 1998; Celato et al 2 013 ) , possibl y due to the inhibition of methylmalonyl-CoA mutase by malonyl-CoA (Gregg et al 1998) . The MMA/MA ratio is less than 1 in malonylCoA decarboxylase deficiency (Gregg et al 1998) . In contrast, in CMAMMA patients, MMA levels exceed those of MA. Mutations in ACSF3 were identified by exome sequencing in patients with combined MMA and MA elevations and negative molecular testing for malonic aciduria (Alfares et al 2011; Sloan et al 2011) .
The clinical significance of CMAMMA is not established to date. The initial three Quebec patients (Alfares et al 2011) , identified through the provincial population urine-based newborn screening (NBS) program (Auray-Blais et al 2007) , were asymptomatic. The other 18 patients described to date (Sloan et al 2011; de Sainvan der Velden et al 2016; Pupavac et al 2016; Reid et al 2016) had a broad range of symptoms (see Suppl. Table 3 ) that brought them to medical attention. The Provincial Neonatal Urine Screening Program (at CHU Sherbrooke) uses urine-soaked filter paper collected by parents at 3 weeks of age to screen directly for elevated MMA and other metabolites (Auray-Blais et al 1979; Sniderman et al 1999; Auray-Blais et al 2007) . As ACSF3-related CMAMMA does not cause accumulation of methylmalonyl-CoA, propionyl-CoA or malonyl-CoA, it is not associated with an abnormal acylcarnitine profile (Alfares et al 2011; Sloan et al 2011) , and hence would not be detected using standard blood-based NBS methods. The Quebec cohort of CMAMMA patients is thus unique in having been ascertained through newborn urine screening rather than through clinical investigation of symptoms and is therefore the only cohort in the world free of selection bias.
In order to further characterize CMAMMA clinically, biochemically, and molecularly, we performed a multicenter retrospective natural history study to identify all known Quebec patients with CMAMMA. The existence in Quebec of asymptomatic patients with normal outcomes despite persistent mild or moderate methylmalonic aciduria had long been recognized (Sniderman et al 1999) and most CMAMMA patients were originally classified as having benign methylmalonic aciduria of unknown etiology. The diagnosis of CMAMMA was established recently after review of the organic acid profiles following the discovery of the biochemical profile of this condition (Alfares et al 2011; Sloan et al 2011) . We contrast the Quebec cohort with the clinical descriptions of all previously reported CMAMMA patients (see Suppl. Table 3 for a summary of all reported cases).
Materials and methods

Patient and data collection
A retrospective medical record review was performed under a multi-institution REB-approved protocol (#MP-CUSM-10-131-PED). Questionnaires (Suppl . Table 1) were sent to metabolic clinicians at all four university hospital centers in the province of Quebec to characterize all known patients with CMAMMA. Clinicians reviewed the medical records and were not asked to perform additional evaluations for the study. Ascertainment was complete according to records of the two biochemical genetic laboratories responsible for organic acid analysis in the province.
Data analysis
The completed questionnaires were analyzed using Microsoft Excel to compute median, minimum, and maximum values for MMA, MA, and MMA/MA ratios from organic acid profiles. Median values were used to minimize the influence of outliers. MMA results using a dedicated MMA assay and those from NBS samples (urine filter papers) were compiled separately. An exact binomial goodness-of-fit test (McDonald 2014) was used to assess whether the clinical signs or symptoms observed in our cohort were significantly overrepresented as compared to their prevalence in the general population.
Organic acid profile analysis
This was done by gas chromatography-mass spectrometry (GC-MS) in biochemical genetics laboratories (at CHU Sherbrooke (CHUS) and CHU Ste-Justine) using similar methods, based on widely-used techniques (Sweetman 1991) . Briefly, samples were treated by oximation, liquid-liquid extraction, and trimethylsilyl (TMS) derivatization. Within the organic acid profile, MMA and MA were identified by selective ion monitoring (SIM) and quantitated relative to a generic internal standard. Samples (from nine patients) exchanged between the two laboratories showed similar MMA values (median difference 7%). A moderate difference in MA values was noted (CHUS median value 35% below that of CHU SteJustine), but did not affect the diagnostic sensitivity of the test.
Dedicated MMA assay
Also using GC-MS, MMA alone was quantitated by stable isotope dilution with a deuterated MMA internal standard.
Population urine NBS
Urine eluted from filter papers was analyzed by thinlayer chromatography (Auray-Blais et al 2007).
Eluates showing MMA elevations were subjected to quantitation by GC-MS (at CHUS). Results above 250 mmol MMA/mol creatinine were considered 'screen-positive' and the infant was referred to a university hospital center. Results between 200 and 250 mmol/mol were considered 'borderline' and prompted a request for a second sample.
ACSF3 analysis
ACSF3 gene sequencing (all nine coding exons) was performed in certified molecular diagnostic laboratories as part of the clinical investigation of patients with a biochemical phenotype compatible with CMAMMA.
Results
Patient characteristics
Twenty-five patients (including four sibling pairs) are reported in this study, representing all currently known patients with CMAMMA in Quebec; 14/25 (56%) were male, and 11/25 (44%) female. The median age was 10.64 years, with a range from 6 months -30 years. 21/25 (84%) were FrenchCanadian; the remainder were of other ethnic/geographical origins (Ashkenazi Jewish/French Canadian, Haitian, Italian/ Syrian, and Bangladeshi). Consanguinity was present in two families (patient 9 and patients 22 & 23). Four patients were reported previously: patients 21, 22, 23 (Alfares et al 2011) , and 5 (Pupavac et al 2016) . The median length of follow-up was 8.3 years (range 0.25 to 28.8 years), for a total of 297.5 patient-years.
Method of ascertainment
All patients but one (96%) were diagnosed as a result of urine NBS, either directly (20/25, or 80%) or following the diagnosis of an older sibling (4/25, or 16%). MMA levels on NBS were available for 19/25 patients (76%) and the median was 460 mmol/mol creatinine (range 198-2416) . Patient 20 was clinically ascertained after presenting at age 4 weeks with severe metabolic acidosis in the context of an episode of bloody diarrhea causing dehydration and hypovolemia. Metabolic evaluation including urine organic acid analysis was performed at that time. The acidosis resolved quickly with fluid resuscitation, and the subsequent course was benign. No sample for urinary newborn screening appears to have been submitted.
Clinical manifestations
We found no specific or consistent pattern of clinical manifestations (Table 1) . Echocardiograms were performed for 8/25 (32%) of patients and were normal except for mild pulmonary valvular stenosis (patient 16) and mild left ventricular dilatation (patient 23) that resolved and did not require cardiology follow-up. Ophthalmologic examinations were performed in 10/25 patients (40%). They were normal except for one patient with congenital unilateral persistent hyperplastic primary vitreous (PHPV) causing glaucoma and cataract, one with bilateral dacryostenosis and one patient with latent nystagmus. Abdominal ultrasound was performed for 7/25 patients (28%) with normal results in 4. One showed unilateral grade 1-2 hydronephrosis with renal cysts, and two had mild and transient increased hepatic volume in infancy.
Apart from patient 20 described above, none had an acute metabolic event. Patient 16 had no metabolic acidosis despite being admitted to ICU for a severe bronchiolitis. Patient 19 had unexplained cycles of nocturnal vomiting beginning in adolescence; abdominal ultrasound, brain MRI and CT scan did not yield a diagnosis, and work-up during one episode showed no metabolic derangement.
Three patients (12%) were diagnosed with ADHD, similar to 11% reported in the pediatric population by the US Center of Disease Control and Prevention (www.cdc.gov) and in other publications (Thomas et al 2015) . One of these patients (4%) also had a specific learning disability (dysorthographia); this proportion is not significantly different from the population prevalence of 9.7% (Altarac and Saroha 2007) (p = 0.51). Another patient had mild language and fine motor delays in early childhood, which corrected by school age.
Five of 25 patients (20%) had various skin manifestations (Table 1) . Regarding gastrointestinal issues, one patient (4%) had bovine protein intolerance in infancy and another (4%) had gastro-oesophageal reflux disease requiring Nissen fundoplication. These observations are not significantly different from the 0.3% prevalence of cow's milk proteininduced enterocolitis (Katz et al 2011) and the 5.4% prevalence of persistent gastro-oesophageal reflux in infants past 1 year old (Nelson et al 1997) , p = 0.08 and p = 1.00, respectively.
Four patients (20%) had congenital anomalies, significantly more than the expected birth prevalence of 3% (Egbe et al 2015) , p = 0.0007. Of these, two (8%) required surgery: one for persistent hyperplastic primary vitreous, one for dacryostenosis. The others -a patient with mild pulmonary valvular stenosis and one with unilateral hydronephrosis (grade 1-2) and a few renal cysts -were asymptomatic and may have only been detected due to their extensive work-up in the context of elevated MMA. Considering only the two clinically significant anomalies, there is no significant difference in prevalence versus the general population (p = 0.17). Another patient (4%) had bilateral vesicoureteral reflux requiring surgical intervention for recurrent urinary tract infections. This proportion is not significantly greater than the population birth prevalence of vesicoureteral reflux of 0.8% ADHD attention deficit hyperactivity disorder, age age at the time of chart review, in years unless otherwise specified, Dx Mode of diagnosis, GERD gastro-oesophageal reflux disease, n/a not available, mo months, NBS diagnosed via urinary newborn screening, the MMA level in mmol/mol creatinine at newborn screening is given in parentheses if available, Pt patient, sib sibling, sx diagnosed via biochemical investigation performed because of clinical symptoms suggestive of an inborn error of metabolism, UTI urinary tract infection (Hiraoka et al 1999) , p = 0.19. There was no biochemical evidence of kidney or liver disease in this cohort. Apart from the single episode of severe gastroenteritis in patient 20, there was no metabolic acidosis, lactic acidosis, hypoglycaemia, or hematologic abnormality reported. Three women (patients 4, 8, and 20) had healthy pregnancies with no abnormalities reported in their children.
Treatment
Ten of 25 patients (40%) received cobalamin at some point. Seven were treated with intramuscular hydroxocobalamin; in all cases, the treatment had no clinical or biochemical effect and was discontinued. Patient 14 had mild vitamin B12 deficiency as a breastfed infant (93 pmol/L, normal 148-722); the mother was vitamin B12 deficient. Patients 19 and 20 also developed mild dietary vitamin B12 deficiency. In all three cases, B12 levels normalized with oral cyanocobalamin supplementation, and this had no significant effect on MMA or MA levels. Overall, B12 levels were available for 22/25 patients and were otherwise normal. Plasma total homocysteine levels, available for 20/25, were all normal. Four patients received L-carnitine supplementation. Patient 20 received this continuously since her early diagnosis of metabolic acidosis in the context of diarrhea (see above). Two siblings (patients 10 and 11) received carnitine (50 mg/ kg/day) from age 4 and 7, respectively, after a mildly increased esterified/free carnitine was observed; the treatment was discontinued at adolescence due to poor compliance. Patients 4 and 20 both received L-carnitine during pregnancy and intravenous dextrose during labor as precautionary measures.
Eleven patients (44%) were initially treated with mild protein restriction; for most, the restriction was lifted, relaxed, or the patients stopped themselves. At present, four patients are still following a mildly protein-restricted diet, and three others are counseled to avoid protein overload without tracking protein intake rigorously. Table 2 presents the median and ranges, for each patient, of the following parameters: plasma MMA (dedicated assay), urine MMA, urine MA, and urine MMA/MA ratio (all obtained from organic acid profile analysis), and specific quantification of urine MMA (dedicated assay).
Biochemical data
As previously reported for CMAMMA (Alfares et al 2011; Sloan et al 2011) , the urine MMA/MA ratio was greater than 1 in each sample from every patient (overall median 10, overall range 2-97). Individual patient median MMA levels from urine organic acid profiles ranged from 107 to 1857 mmol/ mol creatinine (overall median 429, reference range < 10). In plasma MMA assay, the range was 8-42 μmol/L (median 16, reference range < 0.4). Notably, there were no elevations of propionyl-CoA metabolites (3-hydroxypropionic acid, methylcitric acid) or tiglylglycine in the urine organic acid profiles, consistent with the known biochemical basis of CMAMMA.
All patients had at least one significantly elevated value for urine MA. The median for individual patients ranged from 9 to 280 mmol/mol creatinine (overall median 40, reference range < 5). Six patients also had at least one organic acid profile in which MA was reported as undetectable; however, all such results were from analyses performed over 13 years ago, and all patients had elevated urine MA in every analysis performed since then. This discrepancy likely reflects recent improvement in analysis, interpretation, and reporting of MA results, partly due to greater awareness that even mild elevations of MA can be significant. Older samples were not available for retesting; the "zero" (undetectable) MA values were therefore excluded from the statistical analysis.
Plasma organic acid profile analysis was performed in four patients: MMA was elevated in all, MA was slightly elevated in two, normal in one, and undetectable in the other (data not shown). Plasma acylcarnitine profiles were available for 13/25 patients (52%) and were essentially normal. Specifically, there were no elevations of C3 (propionyl), C3DC (malonyl) or C4DC (sum of methylmalonyl and succinyl) carnitines, and no reduction in free carnitine. Urine acylglycine profiles were analyzed for 16 patients, using a sensitive LC-MS/MS method (Bherer et al 2015) ; all were normal. Urine NMR studies were performed on samples from a few patients, by Wevers and colleagues (Engelke et al 2014) . The NMR spectra showed elevated MMA and MA, without revealing abnormalities of any other metabolites.
Molecular data
As shown in Table 3 , ACSF3 sequencing or detection of familial mutations was performed in 19/25 patients (76%). If one assumes that siblings carry the same mutation, the number of patients for whom the causal mutations are known is 20/25 (80%). Parental studies were available for six patients and showed the expected segregation.
All mutations were missense apart from a splice site mutation representing 2/50 alleles in our cohort (c.1239 + 2 T > G) and three frameshift mutations (c.1718delT, c.774_775del, and c.1446 . All genotyped patients carried at least one missense allele. Excluding siblings, the most common mutations were c.1075G > A (p.E359K), representing 38.2% of alleles, and c.1672C > T (p.R558W), representing 20.6% of alleles. Similarly, all identified mutations were missense in the cohort described by Sloan et al (2011) except c.1567C > T (p.R523X), which represented 1/16 (6.25%) alleles. Their most common allele (second most common in our cohort), c.1672C > T (p.R558W), accounted for 31.5% of alleles, while c.1075G > A (p.E359K) (the most common in our cohort) was only observed once (6.25% of alleles). Novel mutations were seen (marked in bold in Table 3 and in Suppl.  Table 3 ), but overall there was substantial overlap of ACSF3 mutations between studies (Suppl. Table 2) (Sloan et al 2011; Lek et al 2016) .
Discussion
We describe the clinical and biochemical course of 25 patients with CMAMMA. The retrospective nature of our study presented certain inherent limitations. Most importantly, we could not initiate additional clinical or imaging investigations, but could only report on what had been done in the course of clinical follow-up. We therefore cannot exclude the possibility of undiagnosed subclinical complications. Even without full investigations, however, the absence of any consistent pattern of overt clinical symptoms despite follow-up for a total of 297.5 patient-years is reassuring. It suggests that CMAMMA is a benign condition, in our unbiased cohort, in the age range represented.
The largely benign clinical course in our cohort stands in contrast to the symptomatic patients described (Sloan et al 2011; de Sain-van der Velden et al 2016; Pupavac et al 2016) . By identifying patients through populationbased newborn screening, our cohort uniquely eliminates selection bias and should more accurately reflect the evolution of CMAMMA. Conversely, all patients from outside Quebec were diagnosed with CMAMMA in the course of investigating various symptoms suggesting a possible metabolic disorder, with one individual ascertained from an exome database of patients with cardiovascular disease (Sloan et al 2011) . It is therefore possible that these symptoms were in fact unrelated to their CMAMMA. n/a not available, duMMA urinary methylmalonic acid in mmol/mol creatinine (as measured by dedicated assay), mo months, pMMA plasma methylmalonic acid in μmol/L (as measured by dedicated assay), median and range given if measured more than once, ref. reference range, uMA urinary malonic acid in mmol/mol creatinine (as measured by organic acid chromatography), median and range given if measured more than once, uMMA urinary methylmalonic acid in mmol/mol creatinine (as measured by organic acid chromatography), median and range given if measured more than once, uMMA/uMA uMMA to uMA ratio, median and range
We cannot, however, completely exclude the possibility of CMAMMA being associated with the onset of clinical manifestations later in life as our oldest patient is 30 years old while 4/9 patients reported by Sloan et al (2011) were older. It is unlikely that specific mutations dictate the phenotype, considering the considerable overlap of ACSF3 mutations in all studies.
Most of our patients were followed by metabolic teams, and many received at some point protein restriction, L-carnitine, and/or sick-day management. It might be suggested that our patients' course was benign due to pre-symptomatic management. Against this is the absence of symptoms despite great variation in management, and that treatment, if any, was discontinued years ago for most patients. Furthermore, our patients were treated on the presumption they had a mild form of classic methylmalonic aciduria. As the biochemical basis and potential pathophysiology of CMAMMA are different, it cannot be assumed that the treatment was in fact appropriate or effective. The fact that patients with CMAMMA do not accumulate either methylmalonyl-CoA or malonyl-CoA means that mechanisms related to acyl-CoA accumulation (Mitchell et al 2008) are not active. By analogy, glutaric aciduria types I (glutaryl-CoA dehydrogenase deficiency) and III (deficient conversion of glutaric acid to glutaryl-CoA (Sherman et al 2008; Marlaire et al 2014) both show high excretion of glutaric acid. While the former is a severe disorder, the latter has not been associated with a consistent clinical phenotype (Knerr et al 2002; Sherman et al 2008) . As in CMAMMA, glutaric aciduria type III (unlike type I) shows a normal acylcarnitine profile (Sherman et al 2008) .
Potential disease-causing mechanisms for CMAMMA would therefore include accumulation of upstream metabolites (MA and MMA), and impairment of mitochondrial fatty acid synthesis due to a lack of intramitochondrial malonyl-CoA. If we posit that ACSF3 deficiency is in fact a benign condition, it becomes necessary to account for the absence of negative effects mediated by these two mechanisms. Mutations not previously reported in the literature are in bold. o -segregation uncertain as parental studies not available n/a not available, Pt patient, sib sibling Accumulations of free MA and MMA were associated with neurotoxicity in vitro (McLaughlin et al 1998) . MA causes mitochondrial toxicity (Stokes et al 2001; Fernandez-Gomez et al 2005) , being a reversible competitive inhibitor of succinate dehydrogenase (SDH) (Stokes et al 2001) , and MMA inhibits the respiratory chain in hippocampal and striatal neurons (Pettenuzzo et al 2006) . Administration of MMA to rodents was associated with central nervous system (Malfatti et al 2003; Bandero et al 2013) and other organ toxicity (Schuck et al 2013) . Knock out (KO) of ACSF3 using CRISPR/Cas9 methods in human cells (Bowman et al 2017) showed defects in mitochondrial metabolism related to SDH inhibition by malonate. Although the concentrations of these metabolites in CMAMMA may be insufficient on their own to produce disease, their accumulation may prove to be a risk factor for multifactorial disease, or effects may become more apparent with age. Acsf3 null mice manifested neuromotor abnormalities that became apparent in adulthood (Epping et al 2015) .
Malonyl-CoA is the starting point for mitochondrial de novo fatty acid synthesis. ACSF3, a mitochondrial acyl-CoA synthetase with high specificity for malonate and methylmalonate, is required for intramitochondrial malonylCoA synthesis (Witkowski et al 2011) . Malonyl-CoA is used to form octanoyl-ACP (an octanoyl moiety bound to acylcarrier protein), the starting point for mitochondrial lipoic acid synthesis. Lipoylation of several mitochondrial proteins (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain ketoacid dehydrogenase, 2-oxoadipate dehydrogenase, and the glycine cleavage system) is essential to their function, and disorders of lipoic acid synthesis are associated with defects of mitochondrial energy metabolism (Mayr et al 2014) . ACSF3 knockdown by RNA interference did not cause a lipoylation defect in vitro (Witkowski et al 2011) . The treated cells in this experiment maintained 37% of ACSF3 activity and 83% of normal octanoyl-ACP. It was speculated that this residual activity permitted adequate lipoic acid synthesis. However, defects in protein lipoylation were not detected in ACSF3 KO cells either (Bowman et al 2017) . Another role emerging for malonyl-CoA is post-translational malonylation of lysine residues in mitochondrial proteins (Bowman et al 2017) . Reduced protein malonylation was observed in ACSF3 KO cells, but the metabolic effects of this remains to be investigated.
None of the patients in our cohort, or previously reported (Alfares et al 2011; Sloan et al 2011; de Sain-van der Velden et al 2016; Pupavac et al 2016; Reid et al 2016) , carry two mutations predicted a priori to be null. Although the residual enzyme activities of the corresponding mutant proteins have not been determined, it is possible that they retain enough activity for mitochondrial functions not to be significantly impacted. It is also plausible that there are alternative mechanisms for the intramitochondrial synthesis of malonylCoA. It was shown in rats that mitochondrial propionyl-CoA carboxylase is capable of converting acetyl-CoA to malonylCoA (Scholte et al 1986) . Hiltunen and colleagues (Hiltunen et al 2010) speculated about the existence of a malonyl-CoA transporter or mitochondrially targeted isoform of acetyl-CoA carboxylase. Recently, a mitochondrial isoform of cytosolic acetyl-coA carboxylase (ACC1) was, in fact, identified and shown to act in concert with ACSF3 to generate mitochondrial malonyl-CoA (Monteuuis et al 2017) .
The frequency of CMAMMA, based on ACSF3 mutant allele frequency studies, was estimated at 1/30,000 (Sloan et al 2011) , implying that the condition is under-diagnosed, probably due to a lack of symptoms in most patients as well as inability to detect CMAMMA by NBS using blood acylcarnitine profiles. Even in Quebec, the observed birth incidence is significantly lower than would be predicted from allele frequencies. Several patients in our study had borderline initial screening results; there were likely others falling just below the cut-off. One sibling with CMAMMA had screening results below the cutoff, but was investigated further as a familial case. Furthermore, follow-up urine and plasma testing focused on MMA and mild elevations of MA were not reported. The diagnostic significance of mildly elevated MA was not obvious (Sniderman et al 1999) prior to the identification of CMAMMA. In this era of 'MMA gene panels' and whole-exome sequencing, additional individuals may be identified without the characteristic biochemical pattern of combined excretion of MMA and MA.
In conclusion, we describe a cohort of 25 largely asymptomatic patients with ACSF3-associated CMAMMA, all but one diagnosed via population-based urine newborn screening. Our findings suggest that CMAMMA is a benign condition. Further study should further clarify its significance, or lack thereof; thus, simplifying management and avoiding for patients the burdens associated with an ambiguous diagnosis (Waisbren et al 2003) . In practice, if CMAMMA is discovered in the course of evaluation of a symptomatic patient, the patient's symptoms should not be attributed to CMAMMA until other potential causes have been eliminated.
